Platelet activating factor (PAF) is implicated in cardiovascular disease (CVD). Statins are widely used in these situations. Therefore, we assessed their effect on the biological activities and metabolism of PAF. Several statins, including simvastatin, exhibited an inhibitory effect against PAF, comparable with that of PAF-inhibitors. Simvastatin also suppressed in vivo PAF-biosynthesis via the de novo pathway, in leukocytes of 6 simvastatin-treated volunteers. Total cholesterol and low-density lipoprotein cholesterol were also significantly decreased, whereas high-density lipoprotein cholesterol, triacylglycerol, EC50, and lag time were unaffected in these participants. Simvastatin with an intact lactone ring also inhibited PAF-activities, while incubation of human mesangial cells with it also resulted in decreased de novo PAF-biosynthesis. This suggests that these simvastatin-dependent effects are independent of its lactone ring. These new actions of statins should be further studied in PAF-implicated pathological conditions such as CVD, cancer, and renal disease.
Davignon J.Cardioprotective and other emerging effects of statins. Int J Clin Pract. 2004;58:49-57.
5.
Davignon J.Emphasis on pleiotropic effects, a new paradigm shift?Coronary Artery Dis. 2004;15(5):223-225.
6.
Zhou Z., Rahme E., Pilote L.Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006; 151(2):273-281.
Ruef J.Interactions of statins with antithrombotic drugs. Medizinische Klinik. 2004;99(2):65-70.
9.
Pahan K.Lipid-lowering drugs. Cellular and Molecular Life Sci. 2006;63(10):1165-1178.
10.
Tsoupras AB , Iatrou C., Frangia C., Demopoulos CAThe implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. Infect Disord Drug Targets.2009;9(4):390-399.
11.
Jadhav SB, Jain GKStatins and osteoporosis: new role for old drugs. J Pharm Pharmacol. 2006;58(1):3-18.
12.
Sterling KA , Tehrani T., Rudnick MRClinical significance and preventive strategies for contrast-induced nephropathy. Curr Opin Nephrol Hypertens . 2008;17(6):616-23.
13.
Lindy O., Suomalainen K., Makela M., Lindy S.Statin use is associated with fewer periodontal lesions: a retrospective study . BMC Oral Health. 2008;8:16.
14.
Demopoulos CA, Pinckard RN, Hanahan DJPlatelet-activating factor-evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979;254(19):9355-9358.
15.
Camussi G., Tetta C., Bussolino F., Andres G., Turello E., Baglioni C.Involvement of cytokines and platelet-activating factor in renal pathology . J Lipid Mediat. 1990;2(suppl):S203-S213.
16.
Montrucchio G., Alloatti G., Camussi G.Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 2000; 80(4):1669-1699.
17.
Demopoulos CA, Karantonis HC, Antonopoulou S.Platelet activating factor-a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol . 2003;105:705-716.
18.
Heon Seo K. , Ko HM, Kim HA, et al. Platelet-activating factor induces up-regulation of antiapoptotic factors in a melanoma cell line through nuclear factor-kappa B activation. Cancer Res. 2006 ; 66(9):4681-4686.
19.
Epstein LG, Gelbard, HAHIV-1-induced neuronal injury in the developing brain. J Leukocyte Biol. 1999;65(4):453-457.
20.
Biancone L. , Cantaluppi V., Boccellino M., et al. Motility induced by human immunodeficiency virus-1 Tat on Kaposi’s sarcoma cells requires platelet-activating factor synthesis. Am J Pathol. 1999;155(5):1731-1739.
21.
Bussolati B. , Biancone L., Cassoni P., et al. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis . Am J Pathol. 2000;157(5):1713-1725.
22.
Alfaro V.Role of histamine and platelet-activating factor in allergic rhinitis . J Physiol Biochem. 2004;60(2):101-111.
23.
Siesjo BK, Katsura K.Ischemic brain damage: focus on lipids and lipid mediators. Adv Exp Med Biol. 1992;318:41-56.
24.
Prescott SM , Zimmerman GA, Stafforini DM, McIntyre TMPlatelet-activating factor and related lipid mediators. Annu Rev Biochem. 2000;69:419-445.
25.
Snyder F.CDP-choline:alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor. Biochim Biophys Acta. 1997; 1348(1-2):111-116.
26.
Francescangeli E., Boila A., Goracci G.Properties and regulation of microsomal PAF-synthesizing enzymes in rat brain cortex. Neurochem Res. 2000;25(5):705-713.
27.
Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SMPlatelet-activating factor, a pleiotrophic mediator of physiological and pathological processes . Crit Rev Clin Lab Sci. 2003;40(6): 643-672.
28.
Bate C., Rumbold L., Williams A.Cholesterol synthesis inhibitors protect against platelet-activating factor-induced neuronal damage. J Neuroinflam. 2007;18:5.
29.
Antonopoulou S., Fragopoulou E., Karantonis HC, et al. Effect of traditional Greek Mediterranean meals on platelet aggregation in normal subjects and in patients with type 2 diabetes mellitus. J Med Food. 2006;9(3):356-362.
30.
Kaesemeyer WH, Caldwell RB, Huang J., Caldwell RWPravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol. 1999;33(1):234-241.
31.
Tsoupras AB , Chini M., Tsogas N., et al. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? AIDS Res Hum Retroviruses . 2008;24(8):1079-1086.
32.
Tsoupras AB , Fragopoulou E., Nomikos T., Iatrou C., Antonopoulou S., Demopoulos CACharacterization of the de novo biosynthetic enzyme of platelet activating factor, DDTinsensitive cholinephosphotransferase, of human mesangial cells. Mediators Inflam. 2007;2007:27683.
33.
Antonopoulou S., Demopoulos CA, Iatrou C., Moustakas G., Zirogiannis P.Platelet-activating-factor acetylhydrolase (Paf-Ah) in human kidney. Int J Biochem. 1994 ;26(9):1157-1162.
34.
Karantonis HC, Antonopoulou S., Perrea DN, et al. In vivo antiatherogenic properties of olive oil and its constituent lipid classes in hyperlipidemic rabbits. Nutr Metab Cardiovasc Dis. 2006 ; 16(3):174-185.
35.
Tsantila N. , Karantonis HC, Perrea DN, et al. Antithrombotic and antiatherosclerotic properties of olive oil and olive pomace polar extracts in rabbits. Mediators Inflam., 2007;2007:36204.
36.
Tsantila N. , Karantonis HC, Perrea DN, et al. Atherosclerosis regression study in rabbits upon olive pomace polar lipid extract administration . Nutr Metab Cardiovasc Dis. 2009 (In Press).
37.
Schnitzer E. , Pinchuk I., Bor A., Fainaru M., Samuni AM, Lichtenberg D.Lipid oxidation in unfractionated serum and plasma. Chem Physics Lipids1998;92(2):151-170.
38.
Bradford MMA rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
39.
Athyros VG, Kakafika AI, Tziomalos K., Karagiannis A., Mikhailidis DPPleiotropic effects of statins-clinical evidence. Curr Pharm Des.2009;15(5):479-489.
40.
White CMPharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol. 1999; 39(2):111-118.
41.
Heuer HOInvolvement of platelet-activating factor (PAF) in septic shock and priming as indicated by the effect of hetrazepinoic PAF antagonists. Lipids. 1991;26(12):1369-1373.
42.
Fletcher JR , DiSimone AG, Earnest MAPlatelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia . Ann Surg1990;211(3):312-316.
43.
Izquierdo I. , Merlos M., García-Rafanell J.Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis . Drugs Today2003;39(6): 451-468.
44.
Zanglis A., Lianos EA, Demopoulos CAThe biological activity of acetylated sphingosylphosphorylcholine derivatives . Int J Biochem Cell Biol. 1996 ;28(1):63.
45.
Tournis S., Demopoulos CA, Siafaka A., et al. Synthesis and biological study of the possible active component of pine pollen. Platelet-Activating Factor. Paper presented at The Second International Conference; October 26-29, 1986; Tennessee, USA.
46.
Eisaf M., Tselepis ADEffect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol. 2003; 66(11):2069-2073.
47.
Carlquist JF , Muhlestein JB, Anderson JLLipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn. 2007;7(5):511-517.
48.
Karabina SA , Ninio E.Plasma PAF-acetylhydrolase: an unfulfilled promise?Biochim Biophys Acta. 2006;1761(11):1351-1358.
Zhang B., Fan P., Shimoji E., et al. Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis. 2006;186(2):291-301.
51.
Beltowski J. , Wojcicka G., Jamroz A.Effect of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities. J Cardiovasc Pharmacol. 2004;43(1): 121-127.
52.
Tsimihodimos V., Karabina SA, Tambaki AP, et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol. 2002;22(2):306-311.
53.
Kom G., Schwedhelm E., Maas R., Schneider L., Benndorf R., Böger R.Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F2trans-isoprostane in hypercholesterolaemic patients. Br J Clin Pharmacol. 2007;63(6):672-679.
54.
Guerra R., Zhao B., Mooser V., Stafforini D., Johnston JM, Cohen JCDeterminants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res. 1997;38(11):2281-2288.
55.
Iatrou C., Moustakas G., Antonopoulou S., Demopoulos CA, Zirogiannis P.Platelet-activating factor (PAF) levels and PAF acetylhydrolase (AH) activities in patients with primary glomerulonephritis (PGN). Nephron . 1996;72(4):611-616.
56.
Satoh K., Imaizumi T., Kawamura Y., et al. Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2. J Clin Invest. 1991; 87(2):476-481.
57.
Wu SC, Shiang JC, Lin SL, et al. Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins. Heart Vessels. 2005 ;20(5):217-223.
58.
Rosenson RS , Wolff D., Tangney CCStatins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia . Clin Sci. 2004;106(2):215-217.
59.
Serradji N. , Bensaid O., Martin M., et al. Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication. J Med Chem. 2000;43(11): 2149-2154.
60.
Sirtori CRTissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacol Ther. 1993;60(3):431-459.
61.
Fragopoulou E., Iatrou C., Demopoulos CACharacterization of acetyl-CoA: lyso-PAF acetyltransferase of human mesangial cells. Mediators Inflamm. 2005;2005(5):263-272.
